Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2289]
News [4632]
Articles [192]
Editorials [8]
Conferences [135]
elearning [9]
Guidelines for cancer care: slipping the net
Guidelines for cancer care: slipping the net
SABCS 2016: BELLE-3 trial meets primary endpoint of progression-free survival for breast cancer
SABCS 2016: BELLE-3 trial meets primary endpoint of progression-free survival for breast cancer
SABCS 2016: Adding an aromatase inhibitor to presurgery treatment for HR/HER2 positive breast cancer provided no additional benefit
SABCS 2016: Adding an aromatase inhibitor to presurgery treatment for HR/HER2 positive breast cancer provided no...
Personalised cancer vaccine associated with promising outcomes for AML patients
Personalised cancer vaccine associated with promising outcomes for AML patients
SABCS 2016 : Adding veliparib to chemotherapy improved response rates among patients with BRCA-mutant breast cancer
SABCS 2016 : Adding veliparib to chemotherapy improved response rates among patients with BRCA-mutant breast cancer
SABCS 2016: Extended letrozole therapy showed limited benefit in postmenopausal women with early-stage, HR-positive breast cancer
SABCS 2016: Extended letrozole therapy showed limited benefit in postmenopausal women with early-stage, HR...
SABCS 2016: Genomic sequencing of treatment-resistant metastatic breast cancer reveals clinically relevant genetic alterations
SABCS 2016: Genomic sequencing of treatment-resistant metastatic breast cancer reveals clinically relevant genetic...
ASH 2016: Additions to standard multiple myeloma therapy do not appear to yield additional benefit
ASH 2016: Additions to standard multiple myeloma therapy do not appear to yield additional benefit
ASH 2016: IKZF1 mutations found to increase hereditary risk for ALL in children
ASH 2016: IKZF1 mutations found to increase hereditary risk for ALL in children
ASH 2016: Nivolumab with chemotherapy improves response, survival in AML study patients
ASH 2016: Nivolumab with chemotherapy improves response, survival in AML study patients

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation